These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20422755)

  • 1. [Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].
    Mazurkova NA; Ryndiuk NN; Shishkina LN; Ternovoĭ VA; Tumanov IuV; Bulychev LE; Skarnovich MO; Kabanov AS; Panchenko SG; Aleĭnikov RP; Il'ina TN; Kuzubov VI; Mel'nikov SIa; Mironov AN; Korovkin SA; Sergeev AN; Drozdov IG
    Vestn Ross Akad Med Nauk; 2010; (3):15-20. PubMed ID: 20422755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of immunogenicity and safety of 2 immunizations with allantoic intranasal live influenza vaccine Ultragrivac].
    Shishkina LN; Mazurkova NA; Ternovoĭ VA; Bulychev LE; Tumanov IuV; Skarnovich MO; Kabanov AS; Ryndiuk NN; Kuzubov VI; Mironov AN; Stavskiĭ EA; Drozdov IG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (4):92-6. PubMed ID: 21916043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
    Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
    Smolonogina TA; Desheva IuA; Rekstin AR; Mironov AN; Rudenko LG
    Vopr Virusol; 2013; 58(6):31-5. PubMed ID: 24772644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The inoculative properties of cold-adapted reassortant A(H5N2) influenza strain during intranasal administration to mice].
    Desheva IuA; Lu Kh; Rekstin AR; Kats DM; Rudenko LG; Klimov AI
    Vopr Virusol; 2007; 52(4):27-30. PubMed ID: 17722607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine.
    Chirkova TV; Naykhin AN; Petukhova GD; Korenkov DA; Donina SA; Mironov AN; Rudenko LG
    Clin Vaccine Immunol; 2011 Oct; 18(10):1710-8. PubMed ID: 21813657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
    Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
    Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenicity of influenza virus H5N2 vaccine strain samples produced by roller cultivation in media with plant derived components].
    Mazurkova NA; Desheva IuA; Shishkina LN; Stavskiĭ EA; Rudenko LG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (3):48-52. PubMed ID: 21812141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple dose vaccination with heterologous H5N2 vaccine: immune response and protection against variant clade 2.2.1 highly pathogenic avian influenza H5N1 in broiler breeder chickens.
    Abdelwhab EM; Grund C; Aly MM; Beer M; Harder TC; Hafez HM
    Vaccine; 2011 Aug; 29(37):6219-25. PubMed ID: 21745517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stimulation of homo- and heterologic T-cell immunological memory in volunteers inoculated with live influenza A (H5N2) reassortant vaccine].
    Naĭkhin AN; Chirkova TV; Petukhova GD; Koren'kov DA; Donina SA; Rudenko LG
    Vopr Virusol; 2012; 57(1):38-42. PubMed ID: 22624472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
    Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral antibody responses to different H5N1 and H5N2 vaccination regimes: implications for the development of autogenously based vaccines.
    Shany SA; El-Kady MF; Eid BT; Hassan ER; Abdel-Moneim AS
    Vet Microbiol; 2011 Dec; 153(3-4):398-402. PubMed ID: 21752557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.